SenzaGen Stock

SenzaGen EBIT

The EBIT of SenzaGen (SENZA.ST) as of Jul 27, 2026 is -11.50 M SEK. In the previous year, EBIT was -18.95 M SEK — a change of -39.32% (higher).

EBIT

-11.50 MSEK

YoY

-39.32%

Last updated:

In 2026, SenzaGen's EBIT was -11.50 M SEK, a -39.32% increase from the -18.95 M SEK EBIT recorded in the previous year.

The SenzaGen EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M SEK)
Date
EBIT (M SEK)
Jan 1, 2019
-37.93 base
Jan 1, 2020
-27.10 base
Jan 1, 2021
-31.53 base
Jan 1, 2022
-20.19 base
Jan 1, 2023
-14.74 base
Jan 1, 2024
-18.95 base
Jan 1, 2025
-11.50 base
Jan 1, 2026 (e)
8.76 base
YEAREBIT (M SEK)
2026 est 8.76
2025 -11.50
2024 -18.95
2023 -14.74
2022 -20.19
2021 -31.53
2020 -27.10
2019 -37.93
2018 -20.73
2017 -16.59
2016 -11.34
2015 -4.88
2014 0.43
Access this data via the Eulerpool API

SenzaGen Revenue

SenzaGen Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
2.72 M SEK
-37.93 M SEK
-50.24 M SEK
Jan 1, 2020
7.96 M SEK
-27.10 M SEK
-27.32 M SEK
Jan 1, 2021
15.42 M SEK
-31.53 M SEK
-31.35 M SEK
Jan 1, 2022
41.77 M SEK
-20.19 M SEK
-24.91 M SEK
Jan 1, 2023
49.87 M SEK
-14.74 M SEK
-22.10 M SEK
Jan 1, 2024
57.70 M SEK
-18.95 M SEK
-17.85 M SEK
Jan 1, 2025
57.97 M SEK
-11.50 M SEK
-11.59 M SEK
Jan 1, 2026 (e)
93.50 M SEK
8.76 M SEK
0.00 SEK

SenzaGen Margins

SenzaGen stock margins

The SenzaGen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SenzaGen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SenzaGen.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
128.49 %
-1,392.33 %
-1,844.24 %
Jan 1, 2020
37.09 %
-340.50 %
-343.24 %
Jan 1, 2021
61.30 %
-204.47 %
-203.26 %
Jan 1, 2022
65.44 %
-48.34 %
-59.64 %
Jan 1, 2023
70.05 %
-29.56 %
-44.31 %
Jan 1, 2024
66.89 %
-32.84 %
-30.94 %
Jan 1, 2025
64.80 %
-19.83 %
-19.99 %
Jan 1, 2026 (e)
64.80 %
9.36 %
0.00 %

SenzaGen Stock analysis

What does SenzaGen do? SenzaGen AB is a Swedish biotechnology company that specializes in the development and marketing of innovative and reliable tests for assessing allergenicity. Founded in 2010 by leading experts from the academic and industry sectors, the company has become a significant player in the field of toxicology. Current methods for assessing allergenicity, such as asthma, eczema, and allergic reactions, are often inaccurate and require the use of animals, which is ethically questionable and expensive. SenzaGen AB has developed a wide range of tests based on biomolecular technologies that use human cells to assess the allergenic reactivity of chemicals and products. These tests are accurate, cost-effective, and meet the current requirements of regulatory authorities and the industry. The company is headquartered in Lund, Sweden, and currently employs about 20 people. SenzaGen AB is a leader in the development of in vitro methods for evaluating allergenicity and utilizes various platform technologies such as gene expression and proteomics analysis, as well as the use of immune cells and keratinocytes. SenzaGen AB's Microarray technology platform, based on DNA-based tests, has been recognized by the European Chemicals Agency (ECHA) as suitable for assessing allergenic reactivity. The company has also partnered with the US biotechnology company In vitro International (IVI) to distribute its allergen tests in the North American market. SenzaGen AB has developed a wide range of products that can be used in various sectors such as cosmetics, food, chemicals, and pharmaceuticals. AllergoDx™ is a test system used by the pharmaceutical and chemical industries to determine the allergenic reactivity of chemicals. GARD™ (Genomic Allergen Rapid Detection) is a rapid test used in the cosmetics and food industries to determine the allergenic reactivity of new products and avoid costly animal testing. GARDskin™ is a skin test used to determine the reactivity of substances that come into contact with the skin, primarily in the chemicals and pharmaceutical industries. Other products in the company's pipeline include GARDpotency™ and GARDair™, which are intended for assessing allergic reactions in industrial and occupational environments. SenzaGen AB has experienced significant growth in recent years and plans to expand its product range and strengthen its market position. The company's business model is based on selling tests and services to chemical, pharmaceutical, food, and cosmetic companies worldwide. Through its innovative technologies and willingness to collaborate with customers, the company has taken a leadership role in toxicology. SenzaGen AB is committed to an ethical and responsible corporate philosophy focused on sustainability and environmental protection. The company has clear goals to meet the growing demand for reliable and ethical testing methods to minimize the impact of chemicals on humans and the environment. SenzaGen is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing SenzaGen's EBIT

SenzaGen's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of SenzaGen's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

SenzaGen's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in SenzaGen’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about SenzaGen stock

EBIT of SenzaGen is -11.50 M SEK in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — SenzaGen

All Key Metrics — SenzaGen